GlobeNewswire

PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING

Share

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (TSX: PMN) (OTCQB: ARFXF) announces that the Company has received approval from the Toronto Stock Exchange to amend the exercise price of an aggregate of 44,182,530 outstanding common share purchase warrants (the “Warrants”) that were previously issued on August 9, 2017, August 28, 2017, October 30, 2017, April 30, 2018, January 22, 2019, June 26, 2019, November 15, 2019, and December 30, 2019 (the “Warrant Repricing”). The Warrants will expire on the date that is five years from the original date of issuance. Outstanding Warrants currently held by Insiders of the Company will be excluded from the Warrant Repricing.

The exercise price of the Warrants is being repriced to CDN $0.13 (USA $0.09) per share, effective April 8, 2020 until May 22, 2020 (the “Warrant Repricing Period”). At the end of the Warrant Repricing Period, the Warrants will revert to the original exercise price. All other terms of the Warrants shall remain the same.

The Company will deliver a new exercise notice (the “New Exercise Notice”) to the Warrantholders for exercise during the Warrant Repricing Period. All Warrantholders who wish to exercise their Warrants during the Warrant Repricing Period will be required to surrender their respective Warrant Certificates representing their Warrants, along with a properly completed New Exercise Notice to the Company, in accordance with the instructions provided in the New Exercise Notice.

Table: List of warrant series subject to repricing:

Date of IssuanceNumber of
Warrants
Outstanding (not
held by Insiders
)
Original
Exercise Price
Expiry Date
August 9, 20174,808,101$   0.30August 9, 2022
August 28, 20172,232,200$   0.30August 28, 2022
October 30, 201777,000$ 0.285August 28, 2022
April 30, 20189,975,228$   0.48April 30, 2023
January 22, 201913,279,269$   0.48January 22, 2024
June 26, 2019280,000$   0.48June 26, 2024
November 15, 20199,939,066$   0.35November 15, 2024
December 30, 20193,591,666$   0.35December 30, 2024
Total:44,182,530

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements.  This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

For further information:
Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn

For media inquiries, please contact:
Shanti Skiffington
shanti.skiffington@gmail.com
Tel. 617 921-0808

For Investor Relations, please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Warrant Repricing and the receipt of TSX approval. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen1.6.2020 19:30:00 CESTPressemelding

Företagsmeddelande, insiderinformation, Helsingfors 1 juni 2020 kl. 20.30 (EEST) Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen FÅR EJ PUBLICERAS ELLER SPRIDAS DIREKT ELLER INDIREKT I FÖRENTA STATERNA, AUSTRALIEN, SYDAFRIKA, HONGKONG, JAPAN, KANADA, SINGAPORE ELLER NÅGON ANNAN STAT DÄR SPRIDNINGEN ELLER PUBLICERINGEN STRIDER MOT LAGEN. Teckningstiden för Nexstim Abp:s (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) företrädesemission om cirka 2,3 miljoner euro (”emissionen”) avslutades 25 maj 2020 i Sverige och 27 maj 2020 i Finland. Enligt det preliminära emissionsutfallet övertecknades emissionen och cirka 273 procent av de tilldelade aktierna tecknades. Av de tilldelade 376 719 780 nya aktierna (”emissionsaktierna”) tecknades 336 033 654 emissionsaktier (cirka 89,2 procent av emissionsaktierna) med företrädesrätt och 40 686 126 emissionsaktier (cirka 10,8 procent av emissionsaktierna) tilldelas i enlighet med emissionsvillkoren. Enligt det preliminära emissio

Nexstim Plc: Preliminary results of the successful rights issue1.6.2020 19:30:00 CESTPress release

Company announcement, inside information, Helsinki, 1 June 2020 at 8:30 pm (EEST) Nexstim Plc: Preliminary results of the successful rights issue NOT FOR PUBLICATION OR DISTRIBUTION, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA OR SINGAPORE, OR IN ANY OTHER COUNTRY WHERE PUBLICATION OR DISTRIBUTION WOULD BE AGAINST THE LAW. The subscription period of Nexstim Plc’s (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “the Company”) rights issue of approximately EUR 2.3 million (“the Share Issue”) ended on 25 May 2020 in Sweden and on 27 May 2020 in Finland. The preliminary results indicate that the Share Issue was oversubscribed and a total of 273% shares were subscribed for of the shares offered. Of the 376,719,780 new shares offered in the Share Issue (“the Offer Shares”), 336,033,654 Offer Shares (approximately 89,2% of the Offer Shares) were subscribed using subscription rights which means that 40,686,126 Offer Shares (approximately 10.8% of

Kinnevik: Valberedning inför årsstämman 20211.6.2020 17:00:00 CESTPressemelding

I enlighet med beslutet vid årsstämman 2020 i Kinnevik AB (publ) (”Kinnevik”) har en valberedning sammankallats, bestående av ledamöter utsedda av Kinneviks röstmässigt största aktieägare. Valberedningen består av Cristina Stenbeck utsedd av Verdere S.à r.l. och CMS Sapere Aude Trust, Hugo Stenbeck utsedd av Alces Maximus LLC, James Anderson utsedd av Baillie Gifford, Anders Oscarsson utsedd av AMF Försäkring & Fonder, Marie Klingspor och Ramsay Brufer utsedd av Alecta. Anders Oscarsson har utsetts till ordförande i valberedningen. Information om valberedningens arbete finns på Kinneviks hemsida, www.kinnevik.com. Aktieägare som önskar lämna förslag till valberedningen kan göra det i skrift till agm@kinnevik.com eller till Valberedningen, Kinnevik AB, Box 2094, 103 13 Stockholm. För ytterligare information, besök www.kinnevik.com eller kontakta: Torun Litzén, Informations- och IR-chef Telefon +46 (0)70 762 00 50 Email press@kinnevik.com Kinnevik är ett sektorfokuserat investmentbolag s

Kinnevik: Nomination committee ahead of the 2021 Annual General Meeting1.6.2020 17:00:00 CESTPress release

In accordance with the resolution of the 2020 Annual General Meeting in Kinnevik AB (publ) (“Kinnevik”), a Nomination Committee has been convened comprising members appointed by Kinnevik’s largest shareholders in terms of voting interest. The Nomination Committee comprises Cristina Stenbeck appointed by Verdere S.à r.l. and CMS Sapere Aude Trust, Hugo Stenbeck appointed by Alces Maximus LLC, James Anderson appointed by Baillie Gifford, Anders Oscarsson appointed by AMF Insurance & Funds, Marie Klingspor and Ramsay Brufer appointed by Alecta. Anders Oscarsson has been appointed Committee Chairman. Information about the work of the Nomination Committee can be found on Kinnevik’s website at www.kinnevik.com. Shareholders wishing to submit proposals to the Nomination Committee can do so in writing to agm@kinnevik.com or to the Nomination Committee, Kinnevik AB, P.O. Box 2094, SE-103 13 Stockholm Sweden. For further information, visit www.kinnevik.com or contact: Torun Litzén, Director Inve

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER1.6.2020 16:20:00 CESTPress release

Bid procedure on 3 June 2020 Certificate:Commercial paper issued in SEK by non-financial companies with a registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 3 December 2020 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 25 May 2020.Bids:Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date:Wednesday 3 June 2020Bid time:0900-0930 hours (CEST) on the Bid dateRequested volume: (corresponding nominal amount)SEK 4 billion Highest permitted bid volume: (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SE

Real People Investment Holdings Limited – Appointment of Director1.6.2020 15:00:00 CESTPress release

The board of Real People Investment Holdings Limited has elected to appoint Mr Ralph Buddle as a non-executive director of the company, with effect from 1 June 2020. Mr Buddle is an experienced senior executive and chartered accountant with 35 years’ experience in retail and FMCG. With a background in corporate finance, M&A and strategy, he also has significant investor relations and corporate governance experience within the JSE Top-40 listed environment. * * * * * * * For further information, please contact: Neil Grobbelaar, Group Chief Executive Officer Email: ctaylor@realpeople.co.za Phone number: +27 82 772 5481 The information was submitted for publication, through the agency of the contact person set out above, on June 1st, 2020 at 15:00 CET Attachment RPIH Press Release - Appointment of director 20200528